Trials / Recruiting
RecruitingNCT07217587
Comparative Efficacy of Nipocalimab and Efgartigimod in Participants With Generalized Myasthenia Gravis
Efficacy and Safety of Nipocalimab vs Efgartigimod for Patients With Generalized Myasthenia Gravis in a Randomized, Open-label, Phase 3b, Interventional Trial Including Within Class Switching From Efgartigimod to Nipocalimab
- Status
- Recruiting
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 115 (estimated)
- Sponsor
- Janssen Research & Development, LLC · Industry
- Sex
- All
- Age
- 18 Years – 74 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to assess how well nipocalimab works when compared to efgartigimod in participants with generalized myasthenia gravis (a condition in which body's immune system mistakenly attacks and damages the connection between nerves and muscles causing muscle weakness).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Nipocalimab | Nipocalimab will be administered intravenously. |
| DRUG | Efgartigimod | Efgartigimod will be administered intravenously. |
Timeline
- Start date
- 2026-01-05
- Primary completion
- 2027-09-28
- Completion
- 2028-12-11
- First posted
- 2025-10-16
- Last updated
- 2026-04-13
Locations
8 sites across 2 countries: United States, Israel
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT07217587. Inclusion in this directory is not an endorsement.